Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

Elan, Wyeth Study Finds Alzheimer’s
Drug Works in ApoE4 Non-Carriers

[July 2, 2008]

By Turna Ray

Although the 18-month Phase II trial did not reach statistical significance on primary efficacy endpoints in the overall study population, post-hoc analyses showed that bapineuzumab yielded “statistically significant and clinically meaningful benefits” in ApoE4 non-carriers on a number of primary endpoints.

Login | Subscribe